FDA Approves DEXMEDETOMIDINE — WG Critical Care, LLC

# FDA Approves WG Critical Care's Dexmedetomidine Injection for Intravenous Use WG Critical Care, LLC has received FDA approval for its intravenous dexmedetomidine hydrochloride formulation, positioning the company to compete in the critical care sedation market dominated by established players. The approval of this sedative-analgesic agent expands treatment options for intensive care settings and could capture market share in the hospital formulary segment.